This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Eliot J. Lazar, MD; David Banks, RPh; Cheryl Graham, MD; David Adams, JD; Peter H. Rheinstein, MD, JD; Mary Gross; Ann M. Witt, JD
US Food and Drug Administration Department of Health and Human Services Rockville, Md

JAMA. 1992;268(1):53-54.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The recent US Food and Drug Administration (FDA) initiative in the area of industry support of scientific and educational activities led to the release of a draft "concept paper" (DCP) in late October 1991.^1-3 The stated objective of this initiative was to define more clearly a category of drug company—supported scientific and educational activity that is not subject to the rules governing advertising and labeling. This clarification is deemed essential so as not to chill industry support of nonpromotional, educational, and scientific programs. Food and Drug Administration officials have stated that the agency's policy is to avoid undue intrusion into continuing medical education and scientific exchange.

The DCP describes this category as "independent scientific and educational activity" and identifies four criteria: independence, objectivity, balance, and scientific rigor, which distinguish it from promotional activity. A number of specific "factors" are listed for each criterion, which would serve . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?